AngioDynamics 'Exceptionally Well-Positioned' For 2026, CEO Says: But Tariffs Still Sting

AngioDynamics Inc. (ANGO) reported a strong Q4 FY2025, with sales of $80.2 million, up 12.7% year-over-year and exceeding estimates, alongside an adjusted loss of 3 cents per share, significantly better than the anticipated 12-cent loss, driven by robust growth in Auryon and Mechanical Thrombectomy sales. For fiscal year 2026, the company projects net sales of $305-$310 million, surpassing consensus, though it anticipates a wider adjusted loss per share of 35-25 cents, partly due to expected tariff impacts. CEO Jim Clemmer emphasized the company's profitability and expanded market opportunities, positioning ANGO for sustained value creation, contributing to a 5.3% stock increase post-announcement.

Analysis

AngioDynamics (ANGO) reported a robust fourth quarter for fiscal year 2025, significantly outperforming consensus estimates on both revenue and profitability. Net sales grew 12.7% year-over-year to $80.2 million, surpassing the expected $74.26 million, while the adjusted loss per share of 3 cents was substantially better than the anticipated 12-cent loss. This top-line strength was driven by impressive performance in key growth segments, particularly a 44.7% surge in Mechanical Thrombectomy revenue and a 19.7% increase in Auryon sales, indicating successful commercial execution. While adjusted EBITDA more than doubled to $3.4 million from $1.5 million a year ago, gross margin contracted by 161 basis points to 52.7%. However, this margin pressure is directly attributable to a $1.6 million tariff impact; absent this, the margin would have been 54.7%. Looking ahead, the company's fiscal 2026 guidance presents a mixed picture. The revenue forecast of $305-$310 million aligns with consensus, but the projected adjusted loss per share of 25 to 35 cents is wider than the 23-cent loss analysts expected. This weaker earnings outlook is explicitly linked to an anticipated $4 million to $6 million tariff impact, highlighting a persistent headwind for profitability despite strong operational momentum.

Key Decisions for Investors

• Investors should weigh the company's demonstrated top-line momentum, driven by high-growth products like Mechanical Thrombectomy, against the persistent margin pressure from tariffs.
• Monitor gross margin and adjusted EBITDA figures in subsequent quarters, as the ability to mitigate tariff impacts will be critical to bridging the gap between strong sales growth and the weaker-than-expected EPS guidance for fiscal 2026.
• The positive stock reaction suggests the market is currently prioritizing the revenue and earnings beat, but long-term value creation will depend on management delivering on its growth catalysts while navigating the guided profitability headwinds.